Introduction
Common epilepsies, the subject of this review, refer to the epilepsy syndromes that we regularly encounter in clinical practice. We focus on the idiopathic generalized epilepsies (IGEs) and temporal lobe epilepsy (TLE) as these are the common epilepsy syndromes in which the role of genetic factors has been investigated. We will not be examining the rare idiopathic epilepsies precipitated by single gene mutations of large effect, nor the genetics of febrile seizures, as these have recently been reviewed [1, 2] .
In reviewing the genetic evidence for common epilepsies, we begin by briefly describing the posited complex genetic architecture of common epilepsies. We examine the methods for genetic dissection for complex diseases, focusing on genetic association studies. We review newer methods, and conclude by offering a perspective on what is needed for future progress.
Monogenic versus complex diseases
Monogenic epilepsies are rare idiopathic epilepsy syndromes due to large effect mutations in a single gene, often ion channels [3] , when both the mutation and the syndrome segregate together and follow simple Mendelian inheritance [1] . They are often characterized by genetic heterogeneity, incomplete penetrance and variable expressivity, with the last two characteristics suggestive of modulation by additional unidentified modifier genes.
In common epilepsy syndromes, however, the underlying genetic architecture is believed to be quite different [4 ] . Instead of a rare mutation in a single gene resulting in epilepsy, common epilepsies are polygenic and result when an individual has susceptibility alleles of sufficient magnitude at enough genes to exceed a putative seizure threshold. An isolated susceptibility allele in a single gene does not, by itself, result in epilepsy. Extension of the concept of genetic heterogeneity to complex epilepsies would imply 'polygenic genetic heterogeneity' with various subsets of susceptibility genes each capable of precipitating clinically identical seizure subsyndromes. The concepts of penetrance and expressivity disappear for complex genetic disorders as the effect of no single gene will dominate the additive or interactive effect of each polygenic set of susceptibility genes.
Common epilepsies are thus termed complex diseases, as the disease does not follow simple Mendelian inheritance, though each susceptibility allele does. Complexity in this 'polygenic' disease is further increased by incorporation of gene-environment interactions [5 ] , the term 'multifactorial' taking the actions of several genes and the environment into account. The mystery of this multifactorial disease lies in our ignorance of the total number of susceptibility genes, distribution of their effect sizes and the magnitude of the required epilepsy precipitating 'effect size' in a given environment.
Susceptibility alleles: rare versus common variants
Much of the variation in the human genome is provided by over 9 million single nucleotide polymorphisms (SNPs) [6] . SNPs and rarer variants are what distinguish individuals within a population from one other; they are believed to represent susceptibility alleles for common diseases with complex inheritance [7 ] .
An ongoing debate, however, centres on the frequency of these susceptibility alleles [8] . Either multiple rare variants (with allele frequencies < 1%) [9] or a few common polymorphisms (SNPs) [10] (allele frequencies > 1%), or both, might play a causal role in complex disease. These models are recognized in complex genetic disorders as the multiple rare variant (MRV) and the common disease-common variant (CDCV) hypotheses.
Both hypotheses are not mutually incompatible, and evidence exists from candidate gene studies to support both hypotheses [8,11,12 ,13] in different complex diseases and within the same complex disease, such as epilepsy. Rare and common variants in CACNA1H [14] and GABRD [15] have been shown to change channel properties consistent with susceptibility to complex IGE but neither accounts for a high proportion of cases, suggesting that in common epilepsies, a mixture of both models is possible [4 ] , and that there is considerable underlying polygenic heterogeneity.
Dissection and disappointment
Several strategies have been attempted for the genetic dissection of common epilepsies and other complex diseases [16 ] ; their strengths and weaknesses have recently been summarized [17 ] . Linkage analysis using multiplex families has proven highly successful for monogenic diseases, but not so in complex diseases and common epilepsies in particular. Affected sib-pair studies, a nonparametric method of linkage analysis, have also proven ineffective in genetic dissection, though these may be a result of the practicalities of ascertaining sample sizes with adequate power.
Genetic association studies
Association studies have been increasingly used as an alternative approach to analyse the common epilepsies. These are, in essence, genetic case-control studies, and represent an epidemiological approach to complex diseases [18 ] . There are theoretical advantages of this strategy over traditional linkage methods in complex diseases [19] . Association studies, however, have been dogged by problems of false-positive results and nonreplicability [20] [21] [22] . Association studies in epilepsy are equally disappointing [7 ,23 ] , with no clear susceptibility gene identified using this approach.
This might be explained by methodologic limitations [7 ,20,23 ,24,25,26 ] ; potential shortcomings include inadequate statistical power [7 ] , inappropriate controls and population stratification [27] , and insufficiently stringent significance thresholds [22, 28] . Genotyping errors may also be contributory [26 ,29,30 ]. Some of these problems may be partially mitigated using designs based on family-based controls and larger sample sizes. Newer statistical techniques to control for bias (especially population stratification [27] ) and multiple testing [31 ] are being developed; careful consideration of significance thresholds [7 ] and use of Bayesian methods [22, 32] are also encouraging developments. Guidelines for epilepsy genetic association studies have been proposed [7 ] , incorporating these improvements.
More troubling, however, is the issue of heterogeneity. As sample sizes increase, it is increasingly likely that the disease population being examined will become more heterogeneous, without the development of greater specificity through endophenotyping. The rare versus common variant debate [8] then becomes of critical importance.
Under the MRV hypothesis, any population contains many rare mildly deleterious mutations that increase epilepsy susceptibility. An individual with epilepsy has several of these rare mutations; unfortunately, different combinations of genes may produce the same epilepsy phenotype. A sample of cases with the same epilepsy syndrome in an association study will thus include a mixture of different rare causative alleles spread across many genes. Such genetic heterogeneity will progressively nullify the statistical power of an association study [9] . In contrast, the most optimistic view is the CDCV hypothesis (in which all susceptibility polymorphisms are common and genetic heterogeneity is minimal), for which association studies will have sufficient power; this assumption has yet to be confirmed for common epilepsies. In reality [4 ] , both common and rare variants are likely to play a role; this will further increase the heterogeneity and reduce the power of association studies.
The rare versus common variant debate also affects sample sizes. Under the CDCV hypothesis, 500-750 case-control pairs would be needed to detect a common susceptibility allele [33 ] . With a rare variant, however, required sample sizes would approach impracticality [9, 34 ].
The sample size further increases with stringent significance thresholds. To complicate matters further, these calculations optimistically assume dominant inheritance, complete linkage disequilibrium between marker and causal allele, and no phenotyping or genotyping error [35 ] . More pragmatic calculations [36] factoring in these considerations [33 ] dictate even larger and more unrealistic sample sizes of thousands or tens of thousands.
Given such daunting sample sizes, multicentre studies will be needed [7 ,23 ] . International League Against Epilepsy (ILAE) diagnostic criteria are a useful starting point for implementation of consistent phenotyping [7 ] . IGE, however, will prove challenging given its clinical heterogeneity; for TLE, aetiologic heterogeneity presents difficulties. Selecting subgroups, for example TLE and hippocampal sclerosis, may be a solution [23 ].
Genome-wide association studies
With falling costs and high-throughput genotyping methods [17 ] , enthusiasm has been mounting for genome-wide association studies. Instead of testing one particular SNP at a time, hundreds of thousands of SNPs are tested throughout the genome for significance. The recent publication of HapMap data [37 ] should make this technically feasible. This method has been used for genetic dissection of myocardial infarction [38] but has yet to be applied to common epilepsies.
While such studies may initially appear attractive due to the ability to seemingly cover the whole genome in one fell swoop, many issues remain. There is no general consensus regarding population selection, marker selection (map-based versus sequence-based), appropriate statistical analyses, population stratification, statistical significance and genotyping errors. These problems and their potential solutions have recently been summarized [17 ,34 ,39,40 ] . One approach which appears to be gaining acceptance is a multistage approach [17 ,40 ] . A small sample is tested for significance with a high-density set of markers; markers that cross the significance threshold are then re-tested in a second, larger population. This results in increased efficiency and significantly reduced cost.
It is likely that genome-wide association studies will be applied to common epilepsies in the near future, if for no better reason than that it will be technically possible to do so. These studies will require meticulous attention to methodology to have any chance of success [17 ] . If candidate genes are identified via genome-wide association studies, biological plausibility is essential.
Given the likely number of false-positive results (despite evolving methods to control for these), each putative susceptibility gene should be shown to be linked to epilepsy in a biologically meaningful way [7 ,41,42] . In epilepsy, for example, alterations in ion channel function [14, 15] would provide functional evidence to validate any statistically significant association.
Metaanalyses of genetic association studies
Given the conflicting results of existing association studies, investigators have turned to metaanalysis to resolve inconsistency. Metaanalysis is an increasingly popular statistical tool for analysing and combining results across studies, producing a conclusion based on the existing body of evidence. Its attraction lies in its ability to combine results of many contradictory small studies, overcome their individual lack of power, and produce a final conclusion as to whether a putative susceptibility gene has a real effect [43 ,44] .
A good metaanalysis relies on robust study selection and statistical analysis. The adage of 'garbage in, garbage out' applies. A metaanalysis must state inclusion and exclusion criteria, as well as assess the methodologic strengths of each study considered [43 ,44,45 ,46] .
Studies to be included must fulfil quality control criteria [46] ; for example, significant deviation from Hardy-Weinberg equilibrium may indicate sampling or genotyping error [47, 48] . Inclusion of methodologically suspect studies would affect the conclusion of the metaanalysis [44] .
A good metaanalysis must also determine and control for heterogeneity of the studies included [44, 46] . Heterogeneity may arise because of differences in ascertainment methods, ethnic populations, case definitions and disease aetiology or severity.
For example, studies examining the relationship between the GABA(B) receptor 1 gene and TLE used two different cohorts -one with predominantly mild nonlesional TLE [49] , the other with predominantly severe TLE with hippocampal sclerosis [50] . Case definitions of drugresistant epilepsy may differ, as seen in recent epilepsy pharmacogenetic studies [51] [52] [53] .
Existing evidence suggests that between-study heterogeneity is prevalent [54] but racial differences are unlikely to account for it [55 ] . There are existing methods for handling heterogeneity such as using a random-effects model or subgroup analysis, but these are not without their problems either [44, 56] .
Publication bias remains a vexing problem in metaanalysis [43 ,57 ] . There is less incentive to submit negative studies for publication because these are less exciting; acceptance is thus more difficult. This naturally leads to a bias towards inclusion of positive studies in metaanalyses, potentially skewing the results towards a positive conclusion.
It is crucial for a robust metaanalysis to ascertain the extent of publication bias; numerous tests exist for this purpose [57 ] . Unpublished data should also be considered for inclusion, though these must still fulfil inclusion and quality control criteria. One way around this problem is to create an online registry of published and unpublished genetic association studies to facilitate metaanalysis [45] . The existing Genetic Association Database [58] is a laudable step in that direction, though its emphasis on published data is unlikely to solve the problem of publication bias. A similar database dedicated to epilepsy association studies, published and unpublished, is required.
Many published association studies in epilepsy are small and underpowered [7 ] . Can metaanalysis find us a small enough genomic region to enable identification of a susceptibility gene for common epilepsies? Its premise is intriguing and its methods are maturing quickly. Encouragingly, minimum standards have recently been proposed [44] . Increasing publication of negative studies is also reducing the problem of publication bias. Metaanalysis has already clarified the relationship between UCHL1 and Parkinson's disease [59] ; common epilepsies may soon benefit from insights provided by careful metaanalyses, though this is no substitute for an adequately powered and designed association study.
Newer methods: multi-locus approaches and admixture mapping
Inventive new approaches may provide fresh insight into epilepsy susceptibility genes.
Multi-locus approaches
Association studies currently examine a single locus at a time. If the CDCV theory is correct, each susceptibility allele only has a small effect, explaining only a small fraction of disease heritability. Finding such genes would require massive sample sizes.
The phenomenon of gene-gene interaction, however, would suggest that though individual effects of each susceptibility gene are small, the joint effect of a pair of genetic variants may be greater than the sum of their individual effects, making identification easier with smaller sample sizes. This is the premise behind multi-locus approaches [6, 60] . These aim to identify genetic variants that act in concert in order to affect disease risk. It is now possible to extend this approach genome wide using extant technology [6] . Initial methodologic concerns [60] have been eased with recent reports that this method is computationally feasible [61 ] and different approaches can be employed for varying models of genegene interaction [6] .
Admixture mapping
An admixed population has genetic ancestry from two different ancestral populations. The possibility of using such populations to map genes was proposed over 50 years ago, but has come into prominence recently due to refinements in its theoretical and practical aspects [62 ,63,64 ] .
At its simplest, admixture mapping is a method of identifying susceptibility alleles that differ in frequency across populations [65] ; it performs best when examining recently admixed populations that have ancestry from two different populations that were previously isolated from each other, and which have large differences in disease prevalence and susceptibility allele frequencies [62 ,63,64 ] .
Admixture mapping occupies a middle ground compared with the established methods of linkage analysis and association analysis for dissection of complex traits [17 ,64 ,65,66] . Its statistical power and mapping resolution falls between linkage analysis and association analysis [64 ,65] , though with caveats [62 ] . It is more robust to genetic heterogeneity and population stratification compared with association analysis [65] . Compared with genome-wide association studies, the number of markers required for a genome scan using admixture mapping is also much lower. This makes admixture mapping an attractive starting point for genome-wide searches.
Though the arguments in favour of admixture mapping are compelling and the statistical methods improving, the biggest obstacle facing this method is availability of suitably admixed populations (with differences in disease and allele frequency), and identifying genetic markers informative for ancestry [62 ] . A set of markers is available for African-Americans [67] , who have 75% African and 25% European ancestry, but it is likely that different sets of markers will be needed for dissimilar populations [65] .
Susceptibility loci for hypertension [68 ] and multiple sclerosis [69 ] have recently been reported using admixture mapping in African-Americans. Admixture mapping is an intellectually appealing concept, but we must be mindful that stringent criteria have to be met [63, 64 ] , and independent replication is pending for these early reports.
Conclusion
Linkage analysis has not yet identified susceptibility genes for common epilepsies, and association studies are now being heavily promoted as a more powerful alternative. Though methodological and statistical innovations have improved study quality, the approach is still dogged by the problem of false-positive reports. Concerns about the genetic architecture of common epilepsies (rare versus common variants) and heterogeneity (clinical and genetic) of epilepsy cases, however, still present fundamental difficulties to this approach. Demonstrating biological plausibility for statistical associations (validation) is rarely carried out, detracting from the impact of the findings. This may require collaboration with other researchers who have complementary skills, such as physiologists, substantiating the biological link between the gene and the phenotype.
Genome-wide association studies, metaanalyses and public databases of existing association studies hold promise for identifying susceptibility genes. Methodological and statistical problems are currently being solved and these studies now appear technically feasible and dependent only on funding. Newer multi-locus approaches and admixture mapping may also be used; multi-locus approaches may be considered for IGE, and admixture mapping for specific populations.
It is instructive to conclude with an overall view of the genetic epidemiology of common epilepsies. The first small steps have been made to identify a small number of epilepsy susceptibility genes by the candidate gene approach [4 ] , but the overwhelming majority await discovery. At the same time, major advances have been made in genotyping speed and costs, statistical analysis and bioinformatics as a complementary strategy to the application of functional genomic approaches to candidate genes. The major advantage of this alternative approach is that it should detect genes which fall outside our current notion of candidate genes.
A multidisciplinary approach involving clinical epileptology, epidemiology, genetics, statistics, bioinformatics and functional genomics is therefore needed [70 ] . The clinician's key role is in assembling and endophenotyping cohorts of epilepsy patients. Large sample sizes must also be balanced against increasing clinical and genetic heterogeneity. The scientist's role is to pursue endophenotyping as close to the molecular level as possible in order to further refine existing clinical entities to reduce the level of heterogeneity which will otherwise confuse attempts to unravel the genetic architecture by the association study approach.
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